Publications
2005
Bergemann R. Charakteristika valider Health-Outcomes-Modelle. Gesundheitsökonomie & Qualitätsmanagement, 2005, Supplement 2, 10: S59-S63.
Bergenstal RM, Gerber RA, Bolinder B, Stern L, Katz LM, Wang L. Cost of diabetes treatment in patients with type 1 or 2 diabetes with or without complications in the United States. Diabetes 2005;54(Suppl 1):A612.
Bergenstal RM, Gerber RA, Bolinder B, Stern L, Katz LM, Wang L. Direct costs of treatment for patients with Type 1 or Type 2 diabetes with or without complications in the USA. In: European Association for the Study of Diabetes; 2005 September; Athens, Greece; 2005.
Berman JM, Lumry WR, Stern LS, et al. A retrospective analysis of medication compliance and disease exacerbation in patients with asthma. In: American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 6; Anaheim, California; 2005.
Buchholz P, Steeds C, Stern LS, et al. Utility assessment among patients with dry eye disease in the UK. In: ISPOR 8th Annual European Congress; 2005 November 8; Florence, Italy; 2005.
Bukstein DA, Murphy KR, Katz LM, McDermott L, Doyle JJ, Patel PA. Adherence with controller therapies and decreased asthma exacerbations in young children. In: American Thoracic Society International Conference; 2005 May; San Diego, California; 2005.
Casciano RN, Walzer S, Müller E. Krankheitsmodell am Beispiel Diabetes - das EAGLE-Modell. Gesundheitsökonomie & Qualitätsmanagement, 2005, Supplement 2, 10: S64-S69.
Chalfin DB, Danis M, Rapoport J, et al. Recursive Partitioning and Amalgamation (RECPAM) to predict ICU survival and length of stay. In: Annual Congress of the Society of Critical Care Medicine; 2005 January; Phoenix, Arizona; 2005.
Chaves PHM, Mody SH, Blasi M, et al. Healthcare costs and resource utilization associated with chronic anemia in older adults; 2005.
Danis M, Chalfin DB, Doyle JJ, et al. Development of model-based computer software for ICU resource allocation. In: Annual Congress of the Society of Critical Care Medicine; 2005 January; Phoenix, Arizona; 2005.
Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and Cardiotoxicity in Older Breast Cancer Patients: A Population-Based Study Journal of Clinical Oncology 2005;23(34):8597-605.
Garver D, Lazarus A, Rajagopalan K, et al. Psychotropic polypharmacy and racial disparities in patients with bipolar disorder. In: American Public Health Association; 2005 November; New Orleans, Louisiana; 2005.
Gieser DK, Williams RT, O'Connell W, et al. Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: A U.S. multi-site retrospective study. International Congress Series 2005;1282C:387-92.
Gieser DK, Williams RT, O'Connell W, et al. Resource utilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. In: Vision 2005; 2005 April; London, England; 2005.
Gieser DK, Williams RT, O'Connell W, et al. Resource utilization of end-stage glaucoma patients receiving low vision care: A US multi-site retrospective study. International Congress Series 2005;1282(In press).
Gieser DK, Williams RT, O'Connell W, et al. Resource utilization of end-stage glaucoma patients receiving visual rehabilitation care: A U.S. multisite retrospective study. In: American Academy of Ophthalmology 2005 Annual Meeting; 2005 October 17-18; Chicago, Illinois; 2005.
Hering D, Piper C, Bergemann R, Hillenbach C, Horstkotte D. Influence of two different reporting systems on counts of thromboembolic and bleeding complications after St. Jude medical valve replacement: results from the GELIA study. J Heart Valve Dis. 2005 Jul;14(4):467-71; discussion 472-5.
Hering D, Piper C, Bergemann R, Hillenbach C, Dahm M, Huth C, Horstkotte D. Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest. 2005 Jan;127(1):53-9.
Janisch HD, Möller B, Priebe P, Rössle M, Pape S, Mauss S, Hartmann P, Freivogel K, Hüppe D: Peginterferon alfa-2a (40KD) plus Ribavirin versus Pegylated interferon alfa-2b (12KD) plus Ribavirin: Ready-to-use syringe (SYR) versus Injector (INJ) (SPRINT). In: 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, USA, Nov 11-15, 2005.
Katz LM, Doyle JJ, Bergemann R, et al. Use of a modified recursive partitioning and amalgamation (RECPAM) technique in outcomes research. In: ISPOR 8th Annual European Congress; 2005 November 6; Florence, Italy; 2005.
Kramer A, Daeschlein G, Kammerlander G, Andriessen A, Aspöck C, Bergemann R et al. Konsensusempfehlung. Geeignete Wirkstoffe zur Wundantiseptik 2. Wirkstoffe zur wiederholten Anwendung auf chronischen, schlecht heilenden bzw. empfindlichen Wunden. Procare, 2005 Nr. 1-2: 20
Kvasz M, Walzer S, Maxion-Bergemann S, Bergemann R, Casciano R. Validation of the economic assessment of glycemic control and long-term effects (EAGLE) diabetes model. In; 2005 October 21-24 San Francisco; 2005.
Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adults and elderly patients: An assessment of outcomes. In: Southwest Allergy Forum: Combined Meeting on Allergy, Asthma and Immunology; 2005 January; Puerto Vallarta, Mexico; 2005.
Marcus P, Oppenheimer EA, Katz LM, Doyle JJ, Patel PA. Use of nebulized budesonide inhalation suspension among older adult and elderly patients: An assessment of outcomes. In: The Western Society of Allergy, Asthma, and Immunology; 2005 January; Kauai, Hawaii; 2005.
Maxion-Bergemann S, Huppertz E, Jacobs LD, Müller E, Walleser S. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model". Int J Clin Pharmacol Ther. 2005 Jun;43(6):271-81.
Montgomery S, Doyle JJ, Stern L, McBurney CR. Economic considerations in the prescribing of third-generation antidepressants. Pharmacoeconomics 2005;23(5):477-91.
Mueller E, Stridde E, Clemens A Huppertz E, Bierwirth R: Entwicklung mikrovaskulärer Langzeit-komplikationen bei Patienten mit Typ-2-Diabetes in der diabetologischen Schwerpunktpraxis: Ergebnisse einer 10-Jahres-Simulation der TEMPO-Patientenkohorte mit dem EAGLE-Diabetes-Modell. In: German Diabetes Society, 40th Annual Meeting, Berlin, Germany, May 4-7, 2005.
Mueller E; Schwander B; Zerwes U; Bergemann R. Klinische und ökonomische Evaluation des diagnostischen Verfahrens "Kapselendoskopie" zur Untersuchung des Dünndarms. DIMDI DAHTA-Datenbank; Dokument-Nr. DAHTA107, Berichts-Nr. ANALYTICA002.
Murphy KR, Bukstein DA, Katz LM, McDermott L, Stern LS, Patel PA. Use of nebulized inhaled corticosteroids is associated with fewer asthma exacerbations in young children. In: American Academy of Allergy, Asthma, and Immunology; 2005 March; San Antonio, Texas; 2005. p. Poster Presentation.
Niederman MS, Chalfin DB, Stern LS, Doyle JJ, Katz LM. Clinical and economic outcomes in patients treated with fluoroquinolone therapy in the intensive care unit. In: 40th ASHP Midyear Clinical Meeting and Exhibition; 2005 December Las Vegas, Nevada; 2005.
Rains BM, Katz LM, Stern LS, Wiederkehr DP, Arikian SR. The use of intranasal amphotericin B in chronic rhinosinusitis patients: A U.S. retrospective chart review. In: American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 4-9; Anaheim, California; 2005.
Rosery H. "Hochfokussierter Ultraschall" ( MRgFUS) - eine neue Therapieoption? Symposium. Charite - Universitätsmedizin Berlin. Klinik für Strahlenheilkunde. March 2005
Rosery H; Thielecke F; Thieme M. Magnetic Resonance Guided Focused Ultrasound Surgery for the Treatment of Uterine Fibroids. DIMDI DAHTA-Datenbank; Dokument-Nr. DAHTA80, Berichts-Nr. ANALYTICA001.
Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics. 2005;23(3):243-57.
Rosery H. HTA - "Prävention" für Screening-Programme? In: Deutsche Agentur für Health Technology Assessment des Deutschen Instituts für medizinische Dokumentation und Information: Informationssystem Health Technology Assessment. 5. Symposium Health Technology Assessment 11. bis 12. November 2004. Screening und Prävention - Nutzen,Kosten, Wirksamkeit. Cologne. Report-Nr. DAHTA20, Teil 1. S. 19-28. http://gripsdb.dimdi.de/de/hta/hta_berichte/hta112_supplement_teil1_de.pdf
Sander B, Gyldmark M, Hayden FG, Morris J, Mueller E, Bergemann R. Influenza treatment with neuraminidase inhibitors: cost-effectiveness and cost-utility in healthy adults in the United Kingdom. Eur J Health Econ. 2005 Sep;6(3):244-52.
Santos C, Stern L, Katz L, Watson T, Gause B. Biovaxid vaccine therapy of follicular lymphoma in first remission: Long-term follow-up of a Phase II trial and status of a controlled, randomized Phase III trial. In: Annual Meeting of the American Society of Hematology; 2005 December; Atlanta, Georgia; 2005.
Schmidt E, Kielhorn A: Patient Compliance in the Treatment of Rheumatoid Arthritis with Biologic DMARDS, and Predicting Factors: a Literature Review. In: ISPOR 8th European Congress, Nov. 6-9, 2005.
Stern LS, Doyle JJ, Katz LM, Dolgitser M. Use of intranasal amphotericin B in chronic rhinosinusitis patients: A survey of US otolaryngologists. In: American College of Allergy, Asthma & Immunology 2005 Annual Meeting; 2005 November 4-9; Anaheim, California; 2005.
Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005;89(10):1245-9.
Walt JG, Buchholz PM, Chiang TH, Stern LS, Doyle JJ. Characterization of end-stage glaucoma patients and use of low vision care services: A survey study. In: Vision 2005; 2005; London, England; 2005.
Walzer S, Maxion-Bergemann S, Bergemann R, Casciano R, Mueller E: Internal Validation of the Economic Assessment of Glycemic Control and Long-term Effects (EAGLE) Diabetes Model. In: ISPOR 8th European Congress, Florence, Italy, Nov. 6-9, 2005.
Walzer S, Maxion-BergemannS, Bergemann R, Casciano R, Mueller E: Validation of the Economic Assessment of Glycemic Control and Long-term Effects (EAGLE) Diabetes Model. In: Society for Medical Decision Making, Annual Meeting, San Francisco, USA, Oct 19-22, 2005.
Weiland O, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Foster GR: Peginterferon alfa-2a (40KD) (PEGASYS¨) plus ribavirin (COPEGUS¨) in treatment-na•ve patients with chronic hepatitis C and genotype 2 or 3 infection: individual estimated probability of sustained virological response (SVR). In: EASL, 40th Annual Meeting of the European Association for the Study of the Liver, Paris, April 13-17, 2005.